Holen Sie sich die Stockscreener-App
0.2282
0.78%
-0.0018
Schlusskurs vom Vortag:
$0.23
Offen:
$0.228
24-Stunden-Volumen:
121.52K
Relative Volume:
0.33
Marktkapitalisierung:
$10.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.36M
KGV:
-0.3097
EPS:
-0.7368
Netto-Cashflow:
-
1W Leistung:
-12.26%
1M Leistung:
-34.86%
6M Leistung:
-80.16%
1J Leistung:
-88.18%
1-Tages-Spanne:
$0.2217
$0.2314
1-Wochen-Bereich:
$0.2027
$0.2636
52-Wochen-Spanne:
$0.2027
$3.89
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Firmenname
Calidi Biotherapeutics Inc
Sektor
Branche
Telefon
(858) 794-9600
Adresse
4475 Executive Drive, Suite 200, San Diego
Vergleichen Sie CLDI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
0.2282 | 10.93M | 0 | -23.36M | 0 | -0.7368 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.22 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.79 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.49 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
555.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.53 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-10-09 | Eingeleitet | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten
Millennium Management LLC Increases Stake in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics Appoints Biotech Veteran Eric Poma, PhD, as CEO to Lead Next Growth Phase - citybuzz -
Jane Street Group LLC Takes Position in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025 - citybuzz -
Calidi Biotherapeutics Presents systemic oncolytic platform - GlobeNewswire
Calidi Biotherapeutics (CLDI) Showcases Innovative CLD-401 Thera - GuruFocus
Revolutionary Cancer Treatment Breakthrough: Calidi's New Systemic Delivery Platform Wows ASCO Conference - Stock Titan
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock - The Globe and Mail
Calidi Biotherapeutics (NYSE:CLDI) Shares Down 5.3% – Time to Sell? - Defense World
Calidi Biotherapeutics, Inc. (CLDI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results And Recent Operational Highlights - marketscreener.com
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights - GlobeNewswire
Calidi Biotherapeutics Secures FDA Green Light for Cancer Trial as New CEO Reveals Q1 Financials - Stock Titan
Candel Therapeutics (NASDAQ:CADL) vs. Calidi Biotherapeutics (NYSE:CLDI) Critical Review - Defense World
Geode Capital Management LLC Buys 120,406 Shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
CLDICalidi Biotherapeutics Inc Latest Stock News & Market Updates - Stock Titan
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5 - The Globe and Mail
Calidi Biotherapeutics (NYSE:CLDI) Stock Price Down 0.3% – Time to Sell? - Defense World
Investor’s Delight: Calidi Biotherapeutics Inc (CLDI) Closes Weak at 0.65, Down -6.53 - DWinneX
Calidi (CLDI) Advances Cancer Treatment with IL15 Superagonist a - GuruFocus
Calidi Biotherapeutics Announces IL15 Superagonist as First - GlobeNewswire
Revolutionary Cancer Treatment Platform Shows Complete Tumor Elimination: First Systemic Delivery Success - Stock Titan
Calidi Biotherapeutics (CLDI) Awards Stock Option to New CEO Eri - GuruFocus
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - The Manila Times
Calidi Bio's Strategic Move: New CEO Secures 726K Share Options with 4-Year Performance Lock - Stock Titan
Calidi Biotherapeutics appoints new CEO By Investing.com - Investing.com South Africa
Zealand names former Lilly exec Singh as CSO - BioCentury
Calidi Biotherapeutics appoints new CEO - Investing.com
Calidi (CLDI) Appoints New CEO as Eric Poma Assumes Leadership | - GuruFocus
Calidi Biotherapeutics Appoints New CEO Eric Poma - TipRanks
Calidi Biotherapeutics Announces Chief Executive Officer Transition And Appointment Of Eric Poma, Ph.D. As CEO And Director - TradingView
Calidi Biotherapeutics Announces Chief Executive Officer - GlobeNewswire
New Calidi Bio CEO Brings $400M Funding Success Record: Strategic Shift for Cancer Treatment Pioneer - Stock Titan
Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor - The Globe and Mail
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24 - The Manila Times
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24 - GlobeNewswire
Cancer Breakthrough Alert: Top Oncologist Reveals New FDA-Cleared Stem Cell Therapy Development - Stock Titan
Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors - The Manila Times
FDA Green Lights Revolutionary Cancer Treatment: Stem Cells Combined With Virus to Fight Multiple Tumors - Stock Titan
Calidi Biotherapeutics Announces Appointment of Guy Travis - GlobeNewswire
Cancer Drug Developer Calidi Bio Strengthens Leadership: Renowned Oncologist Takes CMO Role - Stock Titan
Calidi Biotherapeutics Appoints New Chief Medical Officer - TipRanks
CLDI stock touches 52-week low at $0.42 amid market challenges By Investing.com - Investing.com South Africa
CLDI stock touches 52-week low at $0.42 amid market challenges - Investing.com India
Press Release Distribution & PR Platform - ACCESS Newswire
ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
HighTower Advisors LLC Makes New Investment in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights - The Manila Times
Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire
CLDI stock plunges to 52-week low, hitting $0.57 amid market challenges By Investing.com - Investing.com South Africa
Calidi Bio Raises Fresh $3.9M Capital to Advance Clinical Programs - Stock Titan
Finanzdaten der Calidi Biotherapeutics Inc-Aktie (CLDI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
0.06%
Kapitalisierung:
|
Volumen (24h):